Upstream Defines Verekitug Phase III Programs After FDA Meetings

Company: Upstream Bio · Drug: Verekitug · Indications: Severe Asthma, Chronic Rhinosinusitis with Nasal Polyps · Trial Stage: Phase III (Planned Q1 2027) · Date: September 1, 2026 Summary Following end-of-Phase II meetings with FDA, Upstream Bio disclosed one placebo-controlled pivotal trial each in severe…